Immucell Stock Today
| ICCC Stock | USD 4.99 0.10 2.04% |
PerformanceInsignificant
| Odds Of DistressBelow Average
|
ImmuCell is trading at 4.99 as of the 16th of March 2025, a 2.04% increase since the beginning of the trading day. The stock's open price was 4.89. ImmuCell has about a 36 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of April 1987 | Category Healthcare | Classification Health Care |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. The company has 8.91 M outstanding shares of which 18.25 K shares are currently shorted by private and institutional investors with about 0.23 trading days to cover. More on ImmuCell
Moving against ImmuCell Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ImmuCell Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Michael Brigham | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsImmuCell can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ImmuCell's financial leverage. It provides some insight into what part of ImmuCell's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ImmuCell (ICCC) is traded on NASDAQ Exchange in USA. It is located in 56 Evergreen Drive, Portland, ME, United States, 04103 and employs 6 people. ImmuCell is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.08 M. ImmuCell conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.91 M outstanding shares of which 18.25 K shares are currently shorted by private and institutional investors with about 0.23 trading days to cover.
ImmuCell currently holds about 11.04 M in cash with (4.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.43.
Check ImmuCell Probability Of Bankruptcy
Ownership AllocationThe market capitalization of ImmuCell is $32.08 Million. ImmuCell secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check ImmuCell Ownership Details
ImmuCell Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Mesirow Fin Investmt Mgmt Intl Equity | 2024-12-31 | 24.4 K | |
| Hightower Advisors, Llc | 2024-12-31 | 21.4 K | |
| Prosperity Planning, Inc. | 2024-12-31 | 16 K | |
| Blackrock Inc | 2024-12-31 | 14.4 K | |
| Ubs Group Ag | 2024-12-31 | 12.6 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 11.6 K | |
| Essex Financial Services, Inc. | 2024-12-31 | 11 K | |
| Hm Payson & Co | 2024-12-31 | 4 K | |
| Bank Of America Corp | 2024-12-31 | 2.1 K | |
| Vanguard Group Inc | 2024-12-31 | 225.6 K | |
| Renaissance Technologies Corp | 2024-12-31 | 137 K |
ImmuCell Historical Income Statement
ImmuCell Stock Against Markets
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share | Quarterly Revenue Growth 0.549 | Return On Assets |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.